Jiaxi Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiaxi Feng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Dan Liu
The forth affiliated hospital of Nanjing Medical University
1 shared publicationJianbo Han
Department of General Surgery Nanjing Red Cross Hospital Nanjing Jiangsu China
1 shared publication- Li Yang
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
1 shared publication Mengci Zhang
The forth affiliated hospital of Nanjing Medical University
1 shared publicationMing Lu
Department of General Surgery The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
1 shared publication- Qinghong Zhao
Department of General Surgery , The Second Affiliated Hospital of Nanjing Medical University , Nanjing , China , njmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 2 November 2021
- Published by Springer Nature in Research Square
Upregulated CCNE1 Correlates with Poor Prognosis, Tumor Immune Infiltration and Escape in Breast Cancer
BackgroundBreast cancer (BC) is the most common malignant tumor in women and widely known for its poor prognosis. More and more research has discovered that cyclin E1 (CCNE1) plays an important role in progression of various types of cancer. But its specific mechanism in BC progression still needs further research to explore.MethodsAt first, we determined the expression and prognostic value of CCNE1 through The Cancer Genome Atlas (TCGA) database and The Genotype-Tissue Expression (GTEx) data. Then, we predicted the upstream non-coding RNAs of CCNE1 through StarBase, GEPIA, and Kaplan-Meier plotter database. We further studied the correlation of CCNE1 expression with BC immune cell infiltration, biomarkers of immune cells and immune checkpoints expression through TIMER and GEPIA databases.ResultsThe results suggested that CCNE1 was significantly upregulated in BC and its high expression was correlated with poor prognosis in BC patients. Next, we identified long noncoding RNA (lncRNA) LINC00511 / microRNA-195-5p (miR-195-5p) / CCNE1 axis as the most potential pathway that could regulate CCNE1 expression in BC through StarBase, GEPIA, and Kaplan-Meier plotter database. Furthermore, our in-depth research discovered that CCNE1 expression level was significantly correlated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in BC.ConclusionIn summary, high expression level of CCNE1 was significantly correlated with poor prognosis, tumor immune infiltration and escape in BC.
- 2 November 2021
- Published by Springer Nature in Research Square
Open AccessUpregulated CCNE1 Correlates with Poor Prognosis, Tumor Immune Infiltration and Escape in Breast Cancer
BackgroundBreast cancer (BC) is the most common malignant tumor in women and widely known for its poor prognosis. More and more research has discovered that cyclin E1 (CCNE1) plays an important role in progression of various types of cancer. But its specific mechanism in BC progression still needs further research to explore.MethodsAt first, we determined the expression and prognostic value of CCNE1 through The Cancer Genome Atlas (TCGA) database and The Genotype-Tissue Expression (GTEx) data. Then, we predicted the upstream non-coding RNAs of CCNE1 through StarBase, GEPIA, and Kaplan-Meier plotter database. We further studied the correlation of CCNE1 expression with BC immune cell infiltration, biomarkers of immune cells and immune checkpoints expression through TIMER and GEPIA databases.ResultsThe results suggested that CCNE1 was significantly upregulated in BC and its high expression was correlated with poor prognosis in BC patients. Next, we identified long noncoding RNA (lncRNA) LINC00511 / microRNA-195-5p (miR-195-5p) / CCNE1 axis as the most potential pathway that could regulate CCNE1 expression in BC through StarBase, GEPIA, and Kaplan-Meier plotter database. Furthermore, our in-depth research discovered that CCNE1 expression level was significantly correlated with tumor immune cell infiltration, biomarkers of immune cells, and immune checkpoint expression in BC.ConclusionIn summary, high expression level of CCNE1 was significantly correlated with poor prognosis, tumor immune infiltration and escape in BC.
- 20 November 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 121 (2) , 1911-1922
microRNA‐501‐5p promotes cell proliferation and migration in gastric cancer by downregulating LPAR1
In spite of the achievement in treatment, the gastric cancer (GC) mortality still remains high. MicroRNAs (miRNAs) are a group of small noncoding RNAs that play a crucial part in tumor progression. In this study, we explored the expression and function of microRNA‐501‐5p (miR‐501‐5p) in GC cell lines. Quantitative real‐time polymerase chain reaction assay results suggested that miR‐501‐5p was significantly upregulated in GC tissues and cell lines. And, the Cell Counting Kit‐8 colony formation and cell migration assay results showed that the downregulation of miR‐501‐5p decreased GC cell proliferation and migration. Besides that, we found that GC cell cycle was arrested in G2 phase and cell apoptosis rate was increased by silencing the expression of miR‐501‐5p in GC cell lines using the flow cytometry. We also found that miR‐501‐5p could directly target lysophosphatidic acid receptor 1 (LPAR1) and negatively regulate LPAR1 expression in GC cell lines by performing dual‐luciferase reporter gene assay and Western blot analysis. And, LPAR1 was significantly downregulated in GC tissues and inversely correlated with miR‐501‐5p expression. Furthermore, LPAR1 downregulation promoted cell proliferation and migration, which were attenuated by cotransfection of miR‐501‐5p inhibitor in GC cells. In conclusion, miR‐501‐5p can promote GC cell proliferation and migration by targeting and downregulating LPAR1. miR‐501‐5p/LPAR1 may become a potential therapeutic target for GC treatment.
- 20 November 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 121 (2) , 1911-1922
microRNA‐501‐5p promotes cell proliferation and migration in gastric cancer by downregulating LPAR1
In spite of the achievement in treatment, the gastric cancer (GC) mortality still remains high. MicroRNAs (miRNAs) are a group of small noncoding RNAs that play a crucial part in tumor progression. In this study, we explored the expression and function of microRNA‐501‐5p (miR‐501‐5p) in GC cell lines. Quantitative real‐time polymerase chain reaction assay results suggested that miR‐501‐5p was significantly upregulated in GC tissues and cell lines. And, the Cell Counting Kit‐8 colony formation and cell migration assay results showed that the downregulation of miR‐501‐5p decreased GC cell proliferation and migration. Besides that, we found that GC cell cycle was arrested in G2 phase and cell apoptosis rate was increased by silencing the expression of miR‐501‐5p in GC cell lines using the flow cytometry. We also found that miR‐501‐5p could directly target lysophosphatidic acid receptor 1 (LPAR1) and negatively regulate LPAR1 expression in GC cell lines by performing dual‐luciferase reporter gene assay and Western blot analysis. And, LPAR1 was significantly downregulated in GC tissues and inversely correlated with miR‐501‐5p expression. Furthermore, LPAR1 downregulation promoted cell proliferation and migration, which were attenuated by cotransfection of miR‐501‐5p inhibitor in GC cells. In conclusion, miR‐501‐5p can promote GC cell proliferation and migration by targeting and downregulating LPAR1. miR‐501‐5p/LPAR1 may become a potential therapeutic target for GC treatment.